Endocrine Abstracts

Obesity is increasingly prevalent amongst individuals with Type 1 Diabetes Mellitus (T1DM), contributing to insulin resistance, poor glycaemic control and increased cardiovascular complications. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are not currently licensed in T1DM but have been shown to be both efficacious with regard to weight loss, glycaemic control, and cardiovascular health, and safe in patients on continuous subcutaneous insulin infusion (CSII). We performed a retrospective chart review of 12 patients attending St. James’s Hospital with a background of T1DM managed by closed-loop CSII, with addition of GLP 1-RA therapy for at least 6 months between May 2022 and July 2025. Parameters assessed were change in weight, HbA1c, total daily dose (TDD) of insulin, time in range (TIR), and hypoglycaemic events before and after GLP 1-RA commencement. Patient age ranged from 26-57 years old, with 5 men and 8 women included. Median weight loss observed was 12 kg, with a range of 5.5-24.6kg. Median reduction in HbA1c was 6.5 mmol/l/mol, with a range of 3-20 mmol/l/mol. Median reduction in TDD was 13 units, with a range of 2-80.9 units. Median increase in TIR was 13.5%, with a range of 6-32%. 10 of 12 patients saw no change in frequency of hypoglycaemia. Of the remaining 2, increase in frequency of hypoglycaemia was less than 4%. Based on this observational analysis, GLP1-RA therapy as an adjunct in patients with T1DM on CSII appears to have beneficial effects on weight and glycaemic control without a significant increase in hypoglycaemia.